Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from CSL ( (AU:CSL) ) is now available.
CSL Limited has provided an updated notification to the ASX covering its ongoing on-market share buy-back program for its ordinary fully paid shares. The latest update, dated 20 February 2026, records that the company had repurchased a cumulative 3,325,015 shares prior to the previous day.
The filing also confirms that CSL bought back an additional 69,497 shares on the previous trading day, continuing a program first notified in August 2025. This sustained buy-back activity underscores the company’s capital management strategy and may signal confidence in its valuation, with potential implications for earnings per share and shareholder returns over time.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$169.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited is a global biotechnology company listed on the ASX, focused on developing and manufacturing vaccines, plasma-derived therapies, and other specialty biopharmaceutical products. The company serves patients with rare and serious diseases and supplies critical therapies to healthcare systems worldwide, positioning it as a key player in the biotech and healthcare sectors.
Average Trading Volume: 1,059,980
Technical Sentiment Signal: Sell
Current Market Cap: A$73.53B
For a thorough assessment of CSL stock, go to TipRanks’ Stock Analysis page.